

Myriad Mental Health Fact Sheet

Myriad Mental Health is a business unit of [Myriad Genetics, Inc.](https://www.myriadgenetics.com/) (NASDAQ: MYGN), a leader in genetic testing and precision medicine. Myriad's GeneSight® Psychotropic test analyzes how a patient's genes may affect outcomes with certain medications commonly prescribed to treat depression, anxiety, ADHD, and other mental health conditions.

The GeneSight Test

The GeneSight test has been ordered by tens of thousands of clinicians for more than two million patients.

- The GeneSight Psychotropic test identifies an individual's genetic variations that may impact how they metabolize or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD and other psychiatric conditions. The GeneSight report:
 - Shows whether there are gene-drug interactions for more than 60 FDA-approved medications including antidepressants, anxiolytics, hypnotics, antipsychotics, stimulants and non-stimulants; to see a list of medications, visit genesight.com/product
 - Includes information on how a patient's smoking status may impact their body's metabolism of certain medications
 - Details the individual's genotypes and phenotypes for five pharmacodynamic genes and nine pharmacokinetic genes. COMT has been included for informational purposes
- The GeneSight MTHFR test analyzes whether an individual has a variation in the MTHFR gene, which may limit their ability to create l-methylfolate

Backed by Multiple Clinical Studies

The clinical validity, clinical utility and economic utility of the GeneSight Psychotropic test have been evaluated in eight clinical studies published in peer-reviewed journals. In fact, it's the only neuropsychiatric pharmacogenomic test backed by such extensive [research](#).

Website: www.genesight.com

Executive Team

- Mark S. Verratti, chief commercial officer, Myriad Genetics
- Fred Fantazzia, president, Mental Health
- Kavita Bhat, PhD, vice president, laboratory operations

Scientific Advisory Board

- **Boadie Dunlop**, MD, MSCR, director and associate professor, Mood and Anxiety Disorders Program, Emory University
- **James L. Kennedy**, MD, FRCP(C), FRSC, head, Tanenbaum Centre for Pharmacogenetics, Centre for Addiction and Mental Health
- **Lawrence Lesko**, PhD, FCP, founding director, Center for Pharmacometrics and Systems Pharmacology, University of Florida
- **Andrew Nierenberg**, MD, endowed chair in psychiatry, Massachusetts General Hospital
- **Erika L. Nurmi**, MD, PhD, medical director, Obsessive-Compulsive Disorder Intensive Outpatient Program, and associate director, Psychiatry Residency Track, University of California-Los Angeles
- **Cathryn Lewis**, PhD, head of department, Social, Genetic and Developmental Psychiatry Centre, King's College, London